Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for March 20, 2013 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   



Big Pharma Plus Drug Research Equals Big Trouble
Changes in pharmaceutical development and research could lead to more untested, defective drugs on the market. 
x-small text small text medium text large text


    March 20, 2013 /24-7PressRelease/ -- In the early years of drug research, the government gave scientists funding to develop and discover new drugs. When discoveries were made, pharmaceutical companies would manufacture the drug, secure the patent and reap the benefits of the newest drug on the market.

A Changing Industry

A lot has changed since then, and according to the Washington Post, the changes may not be for the better. Pharmaceutical companies are funding their own research now, and in doing so, can circumvent the built-in checks and balances that existed when outside agencies did the funding and separate scientists did the research.

When a pharmaceutical company funds the study, conducts the study and publishes the results, it should have the end-users' needs in mind. This is not always the case. Pharmaceutical companies have been known to rush defective drugs to the market.

For example, when GlaxoSmithKline introduced the diabetic drug Avandia into the market, it did so with a 17-page article in the New England Journal of Medicine (NEJM), touting Avandia as the best drug, and claiming its competitors paled in comparison. Medical professionals believed GlaxoSmithKline, and Avandia quickly became the go-to drug for diabetes treatment.

Four years later, however, the drug had not only fallen out of favor; it had ceased to exist. The drug was taken off the market after it was found that it dramatically increased the risk of heart attacks. Avandia was directly connected to more than 83,000 heart attacks that resulted in deaths.

Could these deaths have been prevented if pharmaceutical companies were not allowed to control the entire research and development process?

Research Shows Troubling Signs in the Industry

GlaxoSmithKline is not the only Big Pharma company controlling each step of the process. According to a review conducted by the Washington Post, the NEJM published 73 articles about original studies for new drugs, drugs approved by the Food and Drug Administration since 2000, and experimental drugs between September 2011 and August 2012. Of the studies reviewed:
- 60 were funded by pharmaceutical companies
- 50 were coauthored by drug company employees
- A lead author in 37 of the studies had previously accepted compensation from the sponsoring drug company

In fact, Big Pharma provides more funding research than the federal government -- according to the Washington Post, pharmaceutical companies spent $39 billion to the National Institute of Health's $31 billion. Until some checks and balances are restored, problems will continue to occur. For now, injured patients must continue to hold pharmaceutical companies liable for creating bad drugs through pharmaceutical litigation.

Article provided by Girardi Keese
Visit us at www.girardikeese.com


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from FL Web Advantage:

Share This Story
Spread this story with Facebook, Twitter, Linkedin, and more.

Bookmark and Share
Contact Information:
FL Web Advantage

E-Mail: Email us Here
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.